Meitheal Gets US Enoxaparin Approval
NKF-Controlled Meitheal Makes Progress With Lovenox Rival
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
You may also be interested in...
Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.
China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.
Armas has kicked off 2020 with the launch of four generic injectables in the US.